Related Experiment Video
Updated: Jun 12, 2026
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
New options with dabigatran etexilate in anticoagulant therapy
Lars Maegdefessel1, Joshua M Spin, Junya Azuma
1Department of Cardiovascular Medicine, Stanford University - School of Medicine, Stanford, CA 94305-5406, USA. maegdefessel@stanford.edu
Insights
Dabigatran etexilate, a direct thrombin inhibitor, offers effective antithrombotic therapy for venous thromboembolism and stroke prevention. Its oral administration and predictable action make it a promising alternative to traditional anticoagulants.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hematology
Background:
- Thrombosis, or blood clotting, is a major cause of death, leading to myocardial infarctions, strokes, and venous thromboembolism.
- Developing safer and more effective antithrombotic drugs is crucial for improving patient outcomes.
- Dabigatran etexilate represents a new class of direct thrombin inhibitors.
Purpose of the Study:
- To evaluate the efficacy and safety of dabigatran etexilate as an antithrombotic agent.
- To compare dabigatran etexilate with existing therapies like enoxaparin and warfarin.
- To highlight the pharmacokinetic and pharmacodynamic properties of dabigatran etexilate.
Main Methods:
- Clinical trials comparing dabigatran etexilate with enoxaparin for venous thromboembolism prevention post-orthopedic surgery.
- Studies assessing dabigatran etexilate against warfarin for stroke prevention in atrial fibrillation patients.
- Pharmacokinetic analysis of oral dabigatran etexilate, including peak plasma concentrations and drug interactions.
Main Results:
- Dabigatran etexilate demonstrated comparable safety and efficacy to enoxaparin in preventing venous thromboembolism.
- In atrial fibrillation, dabigatran etexilate showed similar stroke/systemic embolism rates to warfarin, with lower hemorrhage rates at 110 mg twice daily.
- Higher doses (150 mg twice daily) showed reduced stroke/systemic embolism rates versus warfarin, with similar major hemorrhage rates.
Conclusions:
- Dabigatran etexilate is a competitive and safe alternative to enoxaparin for venous thromboembolism prevention.
- Its favorable safety and efficacy profile in atrial fibrillation suggests it is a viable alternative to warfarin.
- The oral bioavailability, rapid onset/offset, and predictable response of dabigatran etexilate position it as an attractive antithrombotic option.
Abstract:
Thrombosis, the localized clotting of blood, occurs in both the arterial and venous circulation, and has a major impact on health outcomes. The primary etiology of myocardial infarctions, and approximately 80% of strokes, is acute arterial thrombosis. In combination this represents the most common cause of death in the Western world, while the third leading cause of cardiovascular-associated death is venous thromboembolism. An understanding of the pathogenic changes in the vessel wall and the blood that result in thrombosis is crucial for developing safer and more effective antithrombotic drugs. Dabigatran etexilate belongs to a new class of direct thrombin inhibitors. Following oral administration, dabigatran reaches peak plasma concentrations within 2 hours, shows linear pharmacokinetics, and a limited (but important) amount of direct drug interactions. Given once daily at 150 mg or 220 mg, it has proven to be competitive with enoxaparin in the prevention of venous thromboembolism after major orthopedic surgery, with a comparable safety profile. For stroke prevention in patients suffering from atrial fibrillation, dabigatran administered at a dose of 110 mg twice daily was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of hemorrhage. Dabigatran given at a dose of 150 mg twice daily, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. Oral bioavailability of dabigatran, together with a rapid onset and offset of action and predictable anticoagulation response, makes this newly available antithrombotic drug an attractive alternative to traditional anticoagulant therapies for numerous thrombosis-related indications.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...